What Standard Protocol Should Clinicians Follow When Transitioning Patients Between Different Light-Based Aesthetic Equipment Or Light Sources? Key Safety Steps For Device Transitions

Do not transfer the previous device’s energy settings directly. When transitioning a patient between light-based aesthetic equipment or light sources, clinicians should treat the new device as a new treatment system: document the prior treatment history, review the new device’s instructions for use, perform a device-specific sensitivity or minimal erythema dose (MED) test, and restart conservatively. A common safety approach is to begin at approximately 70% of the newly established MED, unless the manufacturer’s protocol or clinical judgment requires a more conservative setting.

The patient’s previous dose is historical context, not a safe starting prescription. Because wavelength, fluence, pulse structure, beam profile, and emission spectrum can change biological response, the new system requires its own sensitivity assessment and carefully documented dose escalation.

Why Previous Settings Cannot Be Transferred

Different wavelengths produce different tissue responses

Light sources that appear similar clinically may interact with tissue very differently. Broadband IPL, narrowband systems, and lasers such as Alexandrite, diode, and Nd:YAG devices differ in wavelength, penetration, pulse delivery, and target chromophore interaction.

The same numerical fluence can therefore produce substantially different heating, photochemical activity, erythema, or tissue injury on another device.

The emission spectrum matters

A broadband source distributes energy across a range of wavelengths, while a narrowband or laser source concentrates energy more selectively. This changes both treatment effect and the patient’s risk of adverse reactions.

A device transition should consequently be treated as a change in biological exposure, not merely a change in hardware.

Prior tolerance does not validate the new setting

A patient’s lack of reaction to one device does not establish tolerance to another. Previous treatment response can inform clinical judgment, but it cannot replace testing with the new equipment.

The Standard Transition Protocol

1. Collect the previous treatment record

Before treatment, obtain and record:

The previous light source and equipment model
Wavelength or emission type, where available
Initial MED or sensitivity-test result
Last effective dose and treatment parameters
Pulse duration, repetition rate, spot size, or other relevant settings
Treatment interval and number of previous sessions
Clinical response and any adverse reactions
Recent changes in medications, skin condition, or photosensitivity

Incomplete records should be treated as a reason for greater caution, not as permission to estimate an equivalent dose.

2. Review the new device requirements

The treating clinician should confirm the new system’s manufacturer instructions, approved indications, contraindications, parameter ranges, and recommended test procedures. The device’s wavelength, fluence, pulse duration, cooling method, spot size, and delivery geometry should be evaluated together.

The new device must also be appropriate for the patient’s skin type, treatment area, target condition, and current clinical status.

3. Perform a new sensitivity test

A new MED or sensitivity test should be performed using the actual device, applicator, wavelength, and treatment mode intended for the procedure. The test area and response should be documented according to the clinic’s protocol and the device manufacturer’s guidance.

Treatment should proceed only after the clinician has assessed the test response and confirmed that the proposed parameters are appropriate.

4. Restart below the new threshold

The first full treatment on the new system should begin with a conservative safety margin below the newly established MED. The primary reference identifies approximately 70% of the new MED as a typical starting point.

This percentage should not be treated as a universal rule for every device, indication, skin type, or treatment area. Manufacturer instructions, the patient’s test response, prior reactions, and the clinician’s risk assessment may justify a lower starting level.

5. Escalate gradually

Subsequent increases should be based on observed clinical response, treatment objectives, and the absence of concerning reactions. The clinician should document each adjustment rather than assuming that the patient can immediately resume the previous schedule or dose.

Unexpected pain, blistering, marked edema, prolonged erythema, pigmentary change, or other abnormal findings should prompt reassessment before further treatment.

Safety Checks Beyond Energy Settings

Confirm photosensitivity risks

Before treatment, screen for factors that may increase light sensitivity or interfere with healing. These include photosensitizing medications, a history of phototoxic reactions, active skin disease, relevant neurologic conditions such as epilepsy, recent isotretinoin use where applicable, suspicious or malignant lesions, and pregnancy when the procedure is not approved for pregnant patients.

The screening should be repeated when treatment is resumed after a significant interval or when the patient’s medications or health status have changed.

Apply wavelength-specific eye protection

Everyone in the controlled treatment area, including the patient, operator, and support staff, requires eye protection appropriate to the active wavelength and optical density. Patient eye protection is especially important during facial and periorbital procedures because eyelid tissue does not provide reliable protection from all wavelengths.

The protection must match the new device rather than being carried over automatically from the previous system.

Inspect the treatment environment

Before each session, inspect delivery fibers, handpieces, protective housings, and other optical components for damage. Remove jewelry and reflective objects near the treatment field, assess reflective surfaces, and control misdirected or scattered radiation.

Damaged fibers and poorly controlled reflections can create ocular and cutaneous hazards even when the nominal treatment parameters are appropriate.

Additional Considerations for Photodynamic Treatments

Manage photosensitizer exposure separately

When a treatment uses a topical photosensitizer, the protocol must account for both the light source and the photosensitizing agent. Excess formulation should be removed after the specified incubation period, which may vary by product, before the light is activated.

The irradiation field should generally cover the lesion and an appropriate surrounding margin; the primary reference identifies a 5 mm border of normal skin as a typical margin for lesion treatment.

Prepare for phototoxic reactions

Photodynamic treatment can cause erythema, edema, stinging, burning, and other reactions associated with reactive oxygen generation. Conservative pain management may include chilled air, ice application, or suitable local anesthetic measures when clinically appropriate.

Treatment parameters should be optimized together rather than adjusted in isolation. Appropriate fluence and shorter photosensitizer incubation may reduce excessive crusting, exfoliation, and post-inflammatory hyperpigmentation when consistent with the approved treatment protocol.

Give explicit post-treatment light restrictions

Patients should receive clear instructions to avoid direct sunlight and high-intensity artificial light after treatment. Depending on the photosensitizer and procedure, strict avoidance may be required for 24 to 72 hours, with the longer period used when clinically indicated.

Physical or inorganic barrier sunscreens, protective clothing, and bland moisturizers or barrier ointments may help reduce exposure and support recovery. Standard UV sunscreen alone may not adequately protect against intense visible light after some phototoxic treatments.

Understanding the Trade-offs

A conservative restart may reduce immediate efficacy

Starting at 70% of the new MED or lower can make the first treatment less aggressive than the patient’s previous session. This is an intentional trade-off: confirming tolerance is more important than preserving the old treatment intensity.

Efficacy can be reassessed and parameters adjusted in later sessions after the new device response is known.

Sensitivity testing adds time and may cause temporary reactions

A test exposure requires additional clinical time and may produce localized erythema or discomfort. Those costs are justified because the test provides patient-specific information that cannot be inferred reliably from a previous machine.

Device equivalence is difficult to establish

Two systems may use the same nominal wavelength but still differ in pulse shape, cooling, beam delivery, calibration, and treatment geometry. Even apparent technical similarity does not establish clinical equivalence.

Clinicians should avoid converting settings through informal ratios unless the manufacturer has validated that conversion for the specific systems and indication.

Protocols are not interchangeable across modalities

LED, IPL, laser, and photodynamic systems have different risk profiles and operating principles. A transition protocol for one modality should not be applied automatically to another, particularly where photosensitizers, high-fluence pulses, or periorbital treatment are involved.

How to Apply This to Your Practice

Use the following decision rules when transitioning a patient:

If your primary focus is patient safety: Treat the new equipment as a new exposure, perform a device-specific MED or sensitivity test, and restart below the new threshold, commonly around 70% of the new MED.
If your primary focus is treatment continuity: Transfer the patient’s clinical history and response data, but do not transfer the previous device’s energy settings without device-specific validation.
If your primary focus is photodynamic therapy: Coordinate light parameters, photosensitizer incubation and removal, pain control, and strict post-treatment light avoidance as one protocol.
If your primary focus is laser or IPL safety: Verify wavelength-specific protective eyewear, inspect optical components, control reflective surfaces, and protect every person in the treatment area.
If your primary focus is consistent clinical governance: Record the device, test exposure, MED, starting dose, treatment response, adverse effects, and every subsequent parameter change.

A careful device transition preserves treatment continuity while recognizing that biological response must be re-established on the new system.

Summary Table:

Step	Action	Key Consideration
1	Document previous treatment history	Include device model, settings, responses, and adverse effects
2	Review new device instructions	Confirm wavelengths, fluence ranges, contraindications, and test procedures
3	Perform new MED test	Use the actual device, wavelength, and mode; record results
4	Start at ~70% of new MED	Adjust based on manufacturer guidelines and clinical judgment
5	Escalate gradually	Increase dose based on observed response and tolerance

Ensure safe and effective device transitions in your clinic. Contact BELIS today for expert guidance and advanced aesthetic equipment tailored to your practice. Get in touch to discuss your needs.